Presents an update on drugs developed for the treatment of cancer as of July 2005. Adverse reactions of GlaxoSmithKline' ondansetron to the pediatric patients included in its study; Effect of the orphan drug status given to Rexahn's RX-0201 on its approval; Changes in the formulation of Sanofi-Synthelabo's oxaliplatin.